With a high population density and over 45% of the global breast cancer incidence, Asia is expected to account for more than half of all TNBC cases, with a large TNBC patient pool, particularly in China and India.
Novotech Publishes Multi-Specific Monoclonal Antibodies Global Clinical Trial Landscape Report
Singapore - Novotech, the leading Asia Pacific centred biotech CRO has published
Read more